The global shingles vaccine market, valued at USD 4.9 billion in 2024, is projected to experience significant growth, reaching USD 12.9 billion by 2034. A robust compound annual growth rate (CAGR) of 10.1% from 2025 to 2034 is expected, fueled by increasing awareness of shingles, its complications, and the aging population.
The rising number of elderly individuals is one of the key drivers behind this market expansion. With age being a major risk factor for shingles, the growing senior demographic is increasing the demand for preventative measures. Alongside this demographic shift, improvements in reimbursement policies have made shingles vaccines more accessible, further supporting the market’s growth.
Health organizations and public health campaigns have played a pivotal role in boosting awareness about the risks associated with shingles, particularly among older adults. These campaigns emphasize the severe complications of the disease, including chronic pain, and promote vaccination as an essential step in preventing these outcomes. This push for education has led to greater vaccine adoption, especially among the elderly and their caregivers, further accelerating the market’s expansion.
The shingles vaccine market is segmented by product type into Shingrix, Zostavax, and SKYZoster. Shingrix currently leads the market, generating USD 4.2 billion in revenue in 2023. Its recombinant formulation offers long-lasting protection, particularly for high-risk groups such as older adults. Shingrix’s durability reduces the need for frequent boosters, making it an attractive, cost-effective option for both consumers and healthcare providers.
The market is also divided by vaccine type into recombinant and live attenuated vaccines. The recombinant vaccine segment dominated in 2023 and is forecast to reach USD 11.3 billion by 2032. These vaccines offer superior efficacy, providing up to 90% protection even in vulnerable populations. Their extended immunity duration reduces the need for repeated doses, making them the preferred choice over live attenuated alternatives.
North America holds a significant share of the shingles vaccine market, generating USD 2.7 billion in revenue in 2023. This dominance is attributed to high levels of awareness, favorable healthcare policies, and strong public health advocacy. Widespread recommendations for shingles vaccination for adults aged 50 and older, coupled with accessible insurance coverage through Medicare and private insurers, further solidify the region’s market position. Additionally, the aging population and proactive health initiatives contribute to North America’s leading role in the global market.
Related topics
